3P Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)

S Pradhan,Y.J Kim,J Park,S-Y Jeong,S.S Koh,K.D Mandakhalikar,J Kim,L Jaison

doi:10.1016/j.annonc.2022.01.065

3P Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)

S Pradhan, Y.J Kim + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2022.01.065

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Mar 1, 2022
License type: publisher-specific-oa

Affiliation: University of Ulsan, Ulsan College

#Pancreatic Adenocarcinoma Upregulated Factor #Inducing Cancer Cell Proliferation + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PAUF plays a key role in PC tumour progression and metastasis by inducing cancer cell proliferation, angiogenesis and evasion of immune surveillance. PBP1510 developed by Prestige Biopharma Limited, is a novel humanized IgG1 mAb that binds to and neutralizes PAUF with high specificity and affinity. There are no targeted therapies against PAUF, making PBP1510 the first in this class.

Full Text